Skip to main content

Santos da Silva Jorge's Form 4 filing

MoonLake Immunotherapeutics (MLTX) · filed Apr 14, 2026

Accession no.
0001213900-26-043647
Filed
Apr 14, 2026
Trade date
Apr 10-13, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market sales total $2.75M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Santos da Silva JorgeCIK 0001920509Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 10, 2026Class A ordinary shares, par value $0.0001 per shareSSaleDisposed−98,127$18.41F2−$1,806,518.072,976,766Direct
Apr 13, 2026Class A ordinary shares, par value $0.0001 per shareSSaleDisposed−51,873$18.23F3−$945,644.792,924,893Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.00 to $19.55. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.41. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)